559 related articles for article (PubMed ID: 34378270)
41. Immune Checkpoint Inhibitor-induced Myositis.
Jayan A; Mammen AL; Suarez-Almazor ME
Rheum Dis Clin North Am; 2024 May; 50(2):281-290. PubMed ID: 38670726
[TBL] [Abstract][Full Text] [Related]
42. A Rare Case of Overlapping Durvalumab-induced Myositis, Takotsubo-like Morphological Changes Caused by Myocarditis, and Myasthenia Gravis.
Saito S; Hontsu S; Hiraoka J; Yamanaka A; Fujioka N; Shimada D; Okuda Y; Sugie K; Muro S
Intern Med; 2024 Apr; ():. PubMed ID: 38658343
[TBL] [Abstract][Full Text] [Related]
43. Consider Myocarditis When Patients Treated with Immune Checkpoint Inhibitors Present with Ocular Symptoms.
Rhee JY; Torun N; Neilan TG; Guidon AC
Oncologist; 2022 May; 27(5):e402-e405. PubMed ID: 35348772
[TBL] [Abstract][Full Text] [Related]
44. Myocarditis-myositis-myasthenia gravis overlap syndrome depending on immune checkpoint inhibitor.
Ünlütürk Z; Karagülmez AM; Hayti B; Erdoğan Ç
J Neurosci Rural Pract; 2023; 14(1):143-144. PubMed ID: 36891103
[TBL] [Abstract][Full Text] [Related]
45. Myasthenia triggered by immune checkpoint inhibitors: New case and literature review.
Gonzalez NL; Puwanant A; Lu A; Marks SM; Živković SA
Neuromuscul Disord; 2017 Mar; 27(3):266-268. PubMed ID: 28109638
[TBL] [Abstract][Full Text] [Related]
46. Prognosis of immune checkpoint inhibitor-induced myasthenia gravis: a single center experience and systematic review.
Qin Y; Chen S; Gui Q; Zhang T; Li Y; Du Z; Lv Y; Du X; Hu Y; Liu Z
Front Neurol; 2024; 15():1372861. PubMed ID: 38633537
[TBL] [Abstract][Full Text] [Related]
47. Mogamulizumab-Associated Myositis With and Without Myasthenia Gravis and/or Myocarditis in Patients With T-Cell Lymphoma.
Virgen CA; Sparks JA; Nohria A; O'Hare MJ; Goyal A; Said JT; Tawa M; LeBoeuf NR; Kupper TS; Fisher DC; Larocca C
Oncologist; 2023 Aug; 28(8):e694-e698. PubMed ID: 37285523
[TBL] [Abstract][Full Text] [Related]
48. Immune checkpoint inhibitor related myositis: an observational, retrospective, pharmacovigilance study.
Yang H; Ding Z; An Z; Zhao Y; Lu H
Expert Opin Drug Saf; 2024 Apr; ():1-6. PubMed ID: 38629402
[TBL] [Abstract][Full Text] [Related]
49. [Distinctive Disease Entity of Neurological Adverse Events Associated with Immune Checkpoint Inhibitors].
Seki M; Suzuki S
Brain Nerve; 2021 Jan; 73(1):35-46. PubMed ID: 33361512
[TBL] [Abstract][Full Text] [Related]
50. Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study.
Fonseca E; Cabrera-Maqueda JM; Ruiz-García R; Naranjo L; Diaz-Pedroche C; Velasco R; Macias-Gómez A; Milisenda JC; Muñoz-Farjas E; Pascual-Goñi E; Gállego Perez-Larraya J; Saiz A; Dalmau J; Blanco Y; Graus F; Martinez-Hernandez E;
Lancet Neurol; 2023 Dec; 22(12):1150-1159. PubMed ID: 37977714
[TBL] [Abstract][Full Text] [Related]
51. Life-threatening immune checkpoint inhibitor-induced myocarditis and myasthenia gravis overlap syndrome treated with abatacept: a case report.
Wakefield C; Shultz C; Patel B; Malla M
BMJ Case Rep; 2021 Nov; 14(11):. PubMed ID: 34728505
[TBL] [Abstract][Full Text] [Related]
52. Immunotherapy-Induced Overlap Syndrome: Myositis, Myasthenia Gravis, and Myocarditis-A Case Series.
Aggarwal N; Bianchini D; Parkar R; Turner J
Case Rep Med; 2024; 2024():5399073. PubMed ID: 38585685
[TBL] [Abstract][Full Text] [Related]
53. [Clinical Features of Myasthenia Gravis as an Immune-related Adverse Event].
Suzuki S
Brain Nerve; 2024 Jan; 76(1):27-32. PubMed ID: 38191136
[TBL] [Abstract][Full Text] [Related]
54. Case Report: The Neuromusclar Triad of Immune Checkpoint Inhibitors: A Case Report of Myositis, Myocarditis, and Myasthenia Gravis Overlap Following Toripalimab Treatment.
Luo YB; Tang W; Zeng Q; Duan W; Li S; Yang X; Bi F
Front Cardiovasc Med; 2021; 8():714460. PubMed ID: 34485412
[TBL] [Abstract][Full Text] [Related]
55. Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians.
Raschi E; Rossi S; De Giglio A; Fusaroli M; Burgazzi F; Rinaldi R; Potena L
Drug Saf; 2023 Sep; 46(9):819-833. PubMed ID: 37341925
[TBL] [Abstract][Full Text] [Related]
56. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature.
Safa H; Johnson DH; Trinh VA; Rodgers TE; Lin H; Suarez-Almazor ME; Fa'ak F; Saberian C; Yee C; Davies MA; Tummala S; Woodman K; Abdel-Wahab N; Diab A
J Immunother Cancer; 2019 Nov; 7(1):319. PubMed ID: 31753014
[TBL] [Abstract][Full Text] [Related]
57. Neurological adverse events of immune checkpoint inhibitors: An update of clinical presentations, diagnosis, and management.
Farina A; Villagrán-García M; Honnorat J
Rev Neurol (Paris); 2023 Jun; 179(5):506-515. PubMed ID: 36934022
[TBL] [Abstract][Full Text] [Related]
58. Asymptomatic Immune Checkpoint Inhibitor-associated Myocarditis.
Tanabe J; Watanabe N; Endo A; Nagami T; Inagaki S; Tanabe K
Intern Med; 2021 Feb; 60(4):569-573. PubMed ID: 33028770
[TBL] [Abstract][Full Text] [Related]
59. Managing suspected myasthenia gravis and myositis induced by pembrolizumab in a Jehovah's Witness sarcoma patient.
Hutchinson A; Eskens D; Chan A; Bhargava A; Bycroft R
J Oncol Pharm Pract; 2024 Jul; 30(5):950-953. PubMed ID: 38523425
[TBL] [Abstract][Full Text] [Related]
60. Clinical features, diagnosis, and management of pembrolizumab-induced myasthenia gravis.
Zhao S; Zhou Y; Sun W; Li Z; Wang C
Clin Exp Immunol; 2023 Mar; 211(2):85-92. PubMed ID: 36426591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
